newsfilter
← Latest News
GlobeNewswire·

Aclaris Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

- Positive Results from Phase 2a Trial of ITK/JAK3 Inhibitor ATI-2138 Presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress, Further Validating ITK as Therapeutic Target; Initiation of